This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Company News for Apr 30, 2024
by Zacks Equity Research
Companies In The News Are: DPZ, BEN, ON, RVTY.
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Revvity (RVTY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 4.26% and 0.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
by Zacks Equity Research
Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Research Productivity
by Zacks Equity Research
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Compared to Estimates, Revvity (RVTY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.
Revvity (RVTY) Launches New Molecular Testing for Newborns
by Zacks Equity Research
Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
Company News for Oct 31, 2023
by Zacks Equity Research
Companies in The News Are: HLIT, JKS, RVTY, ON.
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow
by Zacks Equity Research
Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.
Revvity's (RVTY) New Launch to Widen Access to Editing Technology
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Revvity (RVTY) Launches Three New Preclinical Research Systems
by Zacks Equity Research
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.